Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

67.70 -2.28 (-3.26%)
Streaming Delayed Price Updated: 3:52 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? ↗
July earnings matter, but long-term growth matters more. 
Via The Motley Fool
News headline image
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out. 
Via MarketBeat
Topics ETFs
News headline image
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound ↗
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound. 
Via MarketBeat
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
DexCom Inc (NASDAQ:DXCM): A GARP Stock with Affordable Growth and Strong Fundamentals ↗
Via Chartmill
News headline image
3 Reasons Investors Love DexCom (DXCM)
DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six months. At the same time, the S&P 500... 
Via StockStory
Topics Stocks
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026? ↗
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out? 
Via The Motley Fool
News headline image
2 Growth Stocks to Buy and Hold for a Decade ↗
They have outpaced the S&P 500 over the past 10 years. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day ↗
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and... 
Via MarketBeat
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Sell in May and Go Away—Starting With These 3 Stocks ↗
Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
2 Mid-Cap Stocks with Impressive Fundamentals and 1 We Question
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
3 Quality Compounders Worth Your Attention
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr... 
Via StockStory
News headline image
5 Insightful Analyst Questions From DexCom’s Q1 Earnings Call
DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not o... 
Via StockStory
Topics Earnings Economy
News headline image
3 Reasons Analysts Love DexCom ↗
Via MarketBeat
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
DXCM Q1 Deep Dive: U.S. Growth Moderates as Product Momentum and Coverage Expansion Drive Strategy
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 bil... 
Via StockStory
News headline image
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
News headline image
DexCom (DXCM) Q1 2026 Earnings Transcript ↗
DexCom (DXCM) Q1 2026 Earnings Transcript 
Via The Motley Fool
Top S&P500 movers in Thursday's after hours session ↗
Via Chartmill
News headline image
DexCom (NASDAQ:DXCM) Exceeds Q1 CY2026 Expectations But Stock Drops
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 15% year on year to $1.19 b... 
Via StockStory
News headline image
2026 Market Cap Madness Championship: Loren v. Emily ↗
It’s time to crown a winner: defending champion Emily Flippen faces off against Cinderella challenger Loren Horst in the Market Cap Madness World Championship. 
Via The Motley Fool
News headline image
DexCom (DXCM) Q1 Earnings: What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what investors should know. DexCom beat analy... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.